Cognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business Update
- Management conference call at 8:30 a.m. ET today -
Source
134 releases originally issued via SEC EDGAR. The issuing organizations are responsible for their content.
- Management conference call at 8:30 a.m. ET today -
Oscar Health Announces Financial Results for Third Quarter 2026 and Raises Full Year 2026 Outlook
Revenues of $465.8 million (13.8% growth year-over-year)
- $24.7 million in Lumvoa™ (veligrotug-vvze) net product revenue with more than 100 patients on therapy at the end of Q3 2026 -
Gross Bookings grew 20% year-over-year on a constant currency basis
Prevention approach aims to keep patients on immune checkpoint inhibitor (ICI) therapy and avoid immunosuppressive irEC treatments, representing an…
Revenue of $326.1 million, in line with the midpoint of guidance
•Biologics License Application for sonelokimab submitted to the U.S. Food and Drug Administration for the treatment of adults and adolescents with…
Marriott Vacations Worldwide Reports
•Revenue of $620 million, up 17% year-over-year with double-digit revenue growth in both segments
Third Quarter Highlights and Recent Developments
•Record total sales; increased 13.3%, with core organic sales up 2.3%